MICHELLE IRVIN: Open Payments
NPI 1184912651 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,683 in 82 payments from 30 companies in 2025. Trend: 2023 $454 · 2024 $1,697 · 2025 $1,683
Food & beverage: $1,683
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 9 | $187 |
| Merck Sharp & Dohme LLC | 8 | $177 |
| Novartis Pharmaceuticals Corporation | 12 | $169 |
| ABBVIE INC. | 8 | $145 |
| Genmab U.S., Inc. | 2 | $124 |
| Eisai Inc. | 5 | $102 |
| PFIZER INC. | 5 | $102 |
| Astellas Pharma US Inc | 3 | $68 |
| Alexion Pharmaceuticals, Inc. | 3 | $67 |
| Daiichi Sankyo Inc. | 3 | $65 |
Products named: EPKINLY, KEYTRUDA, Lenvima, VENCLEXTA, IBRANCE, ULTOMIRIS, RYBREVANT, KISQALI.
Industry payments across KY — which companies pay providers there.
